This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignees: Biointegrence Inc., Hiroshima Industrial Promotion Organization, Riken Corporation. Active years: 2011.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2011
Title: Innovations of Tatsuhiko Tsunoda
Introduction
Tatsuhiko Tsunoda is a notable inventor based in Yokohama, Japan. He has made significant contributions to the field of medical science, particularly in the treatment of liver diseases. His innovative approach has led to the development of a unique method that enhances the effectiveness of hepatocyte transplantation.
Latest Patents
Tsunoda holds a patent for a method of treating mice carrying human hepatocytes. This method involves transplanting human adult hepatocytes into an immunodeficient hepatopathy mouse. Following the transplantation, human growth hormone is administered to elevate the replacement ratio of the transplanted human adult hepatocytes. Additionally, this method improves fatty liver conditions in mice where a significant percentage of hepatocytes have been replaced by human hepatocytes. He has 1 patent to his name.
Career Highlights
Throughout his career, Tatsuhiko Tsunoda has worked with various organizations, including Biointegrence Inc. and Hiroshima Industrial Promotion Organization. His work has focused on advancing medical treatments and improving patient outcomes through innovative research and development.
Collaborations
Tsunoda has collaborated with several professionals in his field, including Chise Mukaidani and Norio Masumoto. These collaborations have contributed to the success of his research and the development of his patented methods.
Conclusion
Tatsuhiko Tsunoda's contributions to medical science through his innovative methods of treating liver diseases highlight his role as a significant inventor. His work continues to influence the field and offers hope for improved treatments in the future.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile